Both Sodium–Glucose Cotransporter-2 (SGLT2) inhibitors and GLP-1 agonists have well-established cardioprotective properties, which is particularly relevant given the high cardiovascular risk in patients with CKD and NAFLD [110]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.